Literature DB >> 9776602

Color Doppler ultrasonography in the earlier differentiation of benign molehydatidiforms from malignant gestational trophoblastic disease.

T Gungor1, M Ekin, H Dumanli, O Gokmen.   

Abstract

BACKGROUND: To find out the effectiveness of color Doppler ultrasonography of the uterine arteries in the differentiation of benign molehydatidiforms from malignant gestational trophoblastic disease.
METHODS: Prospective study was performed in 32 women who were referred to the Oncology Department with the diagnosis of gestational trophoblastic disease. Uterine artery Doppler studies were made and resistance index for both uterine arteries were calculated. In the follow-up, twelve of these patients required chemotherapy (first group) and 20 of them were treated with only suction curettage (second group). Non parametric Mann Whitney U test was used for the statistical analysis.
RESULTS: Median of the lowest uterine artery resistance index were 0.29 for the first group and 0.46 for the second group. Resistance index were significantly lower in the first group (alpha<0.001). Color Doppler study of the uterine arteries is helpful in the differentiation of benign molehydatiforms from malignant gestational trophoblastic disease.

Entities:  

Mesh:

Year:  1998        PMID: 9776602

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  2 in total

1.  Uterine artery Doppler flow velocimetry parameters for predicting gestational trophoblastic neoplasia after complete hydatidiform mole, a prospective cohort study.

Authors:  Flavia Tarabini Castellani Asmar; Antonio Rodrigues Braga-Neto; Jorge de Rezende-Filho; Juliana Marques Simões Villas-Boas; Rafael Cortés Charry; Izildinha Maesta
Journal:  Clinics (Sao Paulo)       Date:  2017-05       Impact factor: 2.365

Review 2.  Is Doppler ultrasound useful for evaluating gestational trophoblastic disease?

Authors:  Lawrence H Lin; Lisandra S Bernardes; Eliane A Hase; Koji Fushida; Rossana P V Francisco
Journal:  Clinics (Sao Paulo)       Date:  2015-12       Impact factor: 2.365

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.